GlassScriptPhysician profile
Karen R Houpt
NPI 1336108463
$1,080.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $219 · 2021: $234 · 2022: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.76 | 2019-2020 | |
| Amgen INC. | $177.04 | 2020-2022 | |
| Genzyme Corporation | $138.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $131.63 | 2019-2022 | |
| Lilly USA, LLC | $90.24 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $72.82 | 2019-2021 | |
| Ucb, INC. | $46.09 | 2019-2020 | |
| Janssen Biotech, INC. | $35.52 | 2021 | |
| Nabriva Therapeutics, Plc | $34.17 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.03 | 2019-2021 | |
| Pfizer INC. | $30.39 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $24.94 | 2019 | |
| Sandoz INC. | $19.31 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $19.05 | 2019 | |
| Epi Health, LLC | $14.94 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $14.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Houpt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.